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REVIEW ARTICLE OPEN
Understanding liver regeneration to bring new insights to the
mechanisms driving cholangiocarcinoma
R. V. Guest1, L. Boulter2, B. J. Dwyer1 and S. J. Forbes1
Cancer frequently arises in epithelial tissues subjected to repeated cycles of injury and repair. Improving our understanding of
tissue regeneration is, therefore, likely to reveal novel processes with inherent potential for aberration that can lead to carcinoma.
These highly conserved regenerative mechanisms are increasingly understood and in the liver are associated with special
characteristics that underlie the organ’s legendary capacity for restoration of size and function following even severe or chronic
injury. The nature of the injury can determine the cellular source of epithelial regeneration and the signalling mechanisms brought
to play. These observations are shaping how we understand and experimentally investigate primary liver cancer, in particular
cholangiocarcinoma; a highly invasive malignancy of the bile ducts, resistant to chemotherapy and whose pathogenesis has
hitherto been poorly understood. Interestingly, signals that drive liver development become activated in the formation of
cholangiocarcinoma, such as Notch and Wnt and may be potential future therapeutic targets. In this review, we summarise the
work which has led to the current understanding of the cellular source of cholangiocarcinoma, how the tumour recruits, sustains
and is educated by its supporting stromal environment, and the tumour-derived signals that drive the progression and invasion of
the cancer. With few current treatments of any true efficacy, advances that will improve our understanding of the mechanisms
driving this aggressive malignancy are welcome and may help drive therapeutic developments.
npj Regenerative Medicine  (2017) 2:13 ; doi:10.1038/s41536-017-0018-z
INTRODUCTION
An enormous unmet clinical need exists for novel therapies in
primary liver tumours; in particular cholangiocarcinoma (CC); a
cancer of the bile ducts. This aggressive malignancy confers a
notoriously poor prognosis; the current overall 5 year survival in
the US is less than 17.5% (ref. 1). Patients often present too late for
the only curative procedure- surgical resection, and investigations
to obtain tissue for diagnostic confirmation are invasive and often
inconclusive. There is currently no serum biomarker of the disease,
which would aid early diagnosis. Carbohydrate antigen (CA) 19-9
is a circulating marker widely used for disease monitoring,
however, its poor sensitivity and specificity, particularly in the
context of cholangitis or cholestasis make it unsuitable for early
disease detection.2 The bile ducts can be sometimes accessed
endoscopically and cellular material obtained via brushing. Much
effort has been made to improve the sensitivity and specificity of
cytological testing using fluorescent in situ hybridisation probes,
however, this technique remains expensive and not in widespread
clinical use.3 Once diagnosis is established, treatment options for
CC are limited. Radical surgical resection requires an extensive,
prolonged procedure and less than 7% of patients have disease
amenable to surgery. Liver transplantation is being pioneered as a
potential option for selected patients with CC, however, many
patients who are intensively screened for this potential curative
procedure are found to not be eligible and do not complete the
rigorous neoadjuvant regimen of chemoradiation. Furthermore,
the long term outcomes on survival or quality of life following liver
transplantation for CC are unknown.4 Studies comparing che-
motherapy either alone or in combination for patients with
unresectable disease have demonstrated partial disease response
rates in the order of 10–30% but only modest effects on overall
survival.5–8 Trials have shown an improvement in progression-free
and overall survival of approximately 3 months in patients
receiving combined gemcitabine/platinum-based chemotherapy
compared to gemcitabine alone.9 These results were corroborated
in a Japanese population with similar effects on outcomes.10 This
combination of chemotherapy is now the accepted standard of
care for patients with advanced CC. Phase II randomised
controlled trials of monoclonal antibodies to the receptor tyrosine
kinases EGFR and VEGFR (known to be overexpressed and
functional in CC) have been disappointing despite encouraging
early results in pre-clinical studies.11–13
Such absence of efficacy in CC, using agents that are well
established to be highly beneficial in other gastrointestinal cancer
types, including metastatic colorectal cancer, is disappointing.
Novel therapeutic avenues, therefore, need to be explored and
this requires an improved and detailed understanding of the
events leading to the initiation and development of CC, how the
tumour is sustained, supported and promoted by its highly
desmoplastic stromal environment and what signals might be
targeted for new treatments.
THE MECHANISMS UNDERPINNING LIVER REGENERATION
FOLLOWING INJURY
In contrast to organ systems such as skin or blood, homeostatic
regeneration of the normal liver is not thought to be dependent
upon stem cell-derived epithelial repopulation.14 Following
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prolonged or severe liver injury the cellular mechanisms of
regeneration of the liver may change, and much research has
focussed on determining the contribution of hepatocyte self-
replication vs. expansion of the putative hepatic progenitor cell
(HPC) population resident in the bile ductules (Fig. 1). There is
consensus that during homeostasis parenchymal turnover is
maintained solely through hepatocyte division controlled by a
selected number of ‘master regulator’ signals including Wnt/β-
catenin and Hippo/Yap.15, 16 This spatiotemporal regulation
contributes to metabolic zonation and determines hepatocyte
function.15, 17 More controversial is the evidence for the cellular
source of parenchymal repair during liver regeneration after injury.
Rodent models including the classical experiment of partial
hepatectomy in the rat, demonstrate that liver size is restored
through hepatocyte hypertrophy and hyperplasia in the remain-
ing lobes; a highly regulated process dependent on changes in
blood flow, the sinusoidal endothelium, immune cells, stellate cells
and a host of growth factors and paracrine signals.18, 19 This
regenerative potential is both highly efficient and of almost
infinite capacity.20, 21 It also appears that when the ability of
hepatocytes to proliferate is inhibited or overwhelmed, the liver
maintains the ability to regenerate via mobilisation of a
population of HPCs.22, 23 However, much debate has surrounded
the true significance of this HPC pool. In zebrafish models, where
hepatocytes are ablated or prevented from entering the cell cycle,
HPCs are activated, proliferate and can restore the hepatocyte
mass ensuring survival of the organism.24
Recent work has proposed a third regenerative mechanism in
the mammalian liver; the transition of hepatocytes into the biliary
state or hepatocyte ‘transdifferentiation’.25, 26 Hepatocyte labelling
studies using chimaeric livers or Cre-based systems have
demonstrated the appearance of biliary-exclusive labels including
CK7 in hepatocyte-derived cells following injury, especially in the
context of bile duct ligation (BDL) or toxin-mediated damage.25, 27
This process can be activated by Notch signalling, as occurs in the
embryonic liver where Notch ligand supplied by the portal
mesenchyme induces differentiation of hepatoblasts into biliary
epithelia.28 Ectopic expression of Notch 1 in fluorescently labelled
adult hepatocytes, using viral delivery of Cre induces co-
expression of hepatocyte and biliary markers as well as changes
in polarity and morphology so that the cells adopt a more biliary
morphology.26 The appearance of this intermediate or ‘bipheno-
typic’ population of cells has been observed in a number of rodent
models of injury and it is postulated that this occurs in human
disease as part of an in vivo cellular reprogramming as a response
to biliary-specific damage.26
DEFINING THE CELL OF ORIGIN IN CC
Similar to the cellular response to benign liver injury and
regeneration, it is now clear that such plasticity of the two
epithelial liver cell types is also exhibited in response to oncogenic
stimuli (Fig. 2). The historical presumption that CC arises from bile
ducts was based on pathological observations of tumours arising
from or adjacent to ductal epithelia or invading into ductal lumina
in addition to immunoreactivity of tumours for cholangiocyte-
specific proteins including CK7 and CK19 (ref. 29). Liver tumours
are described which display features of both CC and hepatocel-
lular carcinoma; so-called combined hepatocellular cholangiocar-
cinoma, with a histopathological subset classified as
cholangiocellular carcinoma (CLC) exhibiting ductular reaction
and cord-like structures resemblant of the Canals of Hering and
are both postulated to arise from progenitor cells.30 Overall these
represent a small minority of tumours with biliary differentiation
and the association of CC with chronic biliary inflammation in
particular chronic liver fluke infection and primary sclerosing
cholangitis (PSC), has added weight to the theory that CC arises
from cholangiocytes.31, 32 However, this assumption has been
challenged following work applying lineage tracing systems to
models of CC. Interpreting these experiments in mouse that aim to
identify the CC cell of origin has been controversial, in part due to
the widely used Albumin-Cre system. Albumin expression in the
perinatal and juvenile liver mirrors the organ’s transition from a
haematopoietic to hepatic function and, therefore, constitutive
albumin Cre systems result in ductular labelling in the adult.33 This
effect has been borne out in a model where kRas mutation and
Pten deletion are used to induce CC under control of the Albumin
promoter. CC is observed in mice receiving Cre induction
shortly after birth (P10), but not at later post-natal time points
(P42) (ref. 34).
Fig. 1 Mechanisms of parenchymal repair in the adult liver after injury. Schematic micrograph showing the contribution made by hepatocytes
vs. hepatic progenitor cells (HPCs) to parenchymal repair under conditions of biliary or hepatocyte damage. In response to biliary injury there
is mobilisation and proliferation of hepatic progenitor cells within a laminin rich niche via myofibroblast-derived signals including Jagged1 to
activate the ‘ductular reaction’. In contrast, hepatocyte targeted injuries including partial hepatectomy stimulate hepatocytes to enter mitosis
and restore liver mass. In the absence of additional superimposed injury, this capacity is almost infinite (up to 90% of liver volume can be
resected in rat), but becomes overwhelmed following chronic or fulminant damage when hepatocytes either undergo necrosis or become
increasingly senescent. It is thought phagocytosis of hepatocyte debris stimulates the HPC response via signals including macrophage-
derived Wnt. PV portal vein, HA hepatic artery, MF myofibroblast, ECM extracellular matrix
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In contrast, labelling in the adult using an inducible biliary-
specific cytokeratin 19 driven Cre system does result in CC arising
from cholangiocytes, when p53 is deleted from cholangiocytes
and then mice are subjected to chronic toxin-mediated damage.35
Histological heterogeneity displayed by CC arising from
different locations along the bile duct supports the findings
from immunohistochemical and gene expression data that
subsets of CC exist; likely arising from cholangiocytes of differing
differentiation states or maturity. For example, perihilar and
some intrahepatic CCs exhibit expression signatures mirroring
those of mature, mucin-producing cholangiocytes of the large
ducts, which share embryological origins with extrahepatic
and pancreatic ductal cells. In contrast other CCs exhibit
profiles aligned with those of the HPCs of the terminal ductules
(CLCs).36
Until recent times the hepatocyte had not been evaluated as a
potential cell of origin for CC, however, given the common
embryological origin of the two cell types and the occurrence of
perivenular CC in the context of chronic hepatocyte injury, e.g.,
hepatitis C virus infection, the hypothesis that mature hepatocytes
could be a cell of origin of CC would appear conceptually
plausible. Indeed there is now good evidence that hepatocyte
conversion into CC is possible when exposed to favourable stimuli,
and the key driver of this process appears to be Notch
signalling.37, 38 Again the use of heritable labelling with inducible
Cre-loxP technology was employed to ‘tattoo’ cells expressing the
albumin locus (at 8 weeks post-natally to ensure exclusive
hepatocyte tracing) (Alb-Cre-ERT2;R26RlacZ/+) or the CK19 locus
(CK19-Cre-ERT2;R26RlacZ/+). After carcinogen exposure using thioa-
cetamide, lacZ-positive tumours with features of biliary differ-
entiation (i.e., CC) were observed only in the Albumin and not the
CK19 labelled animals, and arose from centrilobular hepatocytes.
To help explain this interesting finding, it was proposed that the
P450 cytochrome enzymes required to produce the carcinogenic
metabolite from thioacetamide are located in this region. To
confirm the requirement of Notch signal in this conversion, the
authors of the study used a construct to either overexpress the
intracellular fragment of Notch1 (N1-ICD) (Alb-CreERT2;R26RNotch/+)
or delete the principal effector of canonical Notch, Hes1 (Alb-
CreERT2;Hes1fl/fl). They observed an increase in the number of
neoplastic ductular nodules in response to Notch1 over-expres-
sion, whereas nodules did not form in animals with deletion of
Hes1 in Albumin-expressing cells.38 These findings have been
corroborated by an alternative fate-tracing study using plasmid
delivery of N1-ICD/AKT into livers of R26ReYFP mice where
hepatocytes were labelled using transthyretin-driven Cre (deliv-
ered using adeno-associated virus). The resulting tumours
expressed eYFP demonstrating they arose from hepatocytes.
One criticism of this paper has been the selection of biliary
markers used to demonstrate biliary differentiation of tumours, in
particular Sox9 and CK8, which are widely regarded to be also
expressed by hepatocytes.37 CC can arise from cells at any point
along the biliary tree; from the large extrahepatic ducts to the
terminal small ductules within the liver.
The genetic tracing evidence supporting further intra- and inter-
tumoural diversity in the cellular origin of CC arising from the liver
parenchyma has deep implications for therapy and adds further
complexity to what is already known to be a highly hetero-
geneous malignancy. Gene expression analysis can distinguish
between tumours arising from different cells of origins as
demonstrated by Holczbauer and colleagues who virally trans-
formed cells at different stages along the hepatic differentiation
lineage (mouse HPCs, lineage-committed hepatoblasts or adult
differentiated hepatocytes) and demonstrated genetic and
phenotypic heterogeneity in the resulting tumours.39 The
implication that differing cells of origin in tumours between
patients and potentially within one individual suggests huge
divergence of somatic mutation profiles, differences in epigenetic
landscapes, activation of signalling pathways and ultimately may
well explain the large variability in patient response to therapy.
Therefore, in the future, adopting a molecular diagnostic approach
to CC may pave the way for personalised medicine where the
therapeutic agents offered could have greater efficacy in that
particular sub-group of CC disease.
Fig. 2 The cell of origin of cholangiocarcinoma. Schematic micrograph of lineage tracing experiments in mouse demonstrating the
contribution of cytokeratin-19-positive ductular cells and albumin or transthyretin-positive hepatocytes to the formation of tumours
exhibiting biliary differentiation. Cholangiocarcinoma can arise from either cholangiocytes, immature ductules or through transdifferentiation
of hepatocytes
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DRIVERS OF THE CELL IDENTITY IN LIVER DEVELOPMENT AND
REGENERATION DRIVE CC: NOTCH, YAP AND WNT
The role of Notch as a crucial determinant of tumour cell
phenotype is consistent with its established role in liver
development, as previously emphasised, where hepatoblast
differentiation is dependent upon the cell’s location relative to
the portal vein mesenchyme and hence exposure to the Notch
ligand JAG1, as well as other signals including TGFβ.40 Evidence
from mouse studies suggest that Notch activation can be a key
driver of CC development, regardless of the cell of origin in which
the initiating mutational events occur (Fig. 3). Canonical Notch
signalling in mammals is characterised by a cell-to-cell signal in
which membrane tethered ligand (Jagged (JAG)1 and 2 and Delta-
like ligand (Dll)1, 3 and 4) can interact with any one of four
receptors (NOTCH1, NOTCH2, NOTCH3 and NOTCH4). This triggers a
series of enzymatic cleavage events within the membrane of the
signal-receiving cell, mediated principally by a complex known as
gamma-secretase. This proteolysis releases a truncated form of the
receptor, the intracellular domain (N-ICD), which is then able to
translocate to the nucleus where it acts to liberate its downstream
target genes from a state of active transcriptional repression. N-
ICD forms a complex with its DNA-binding partner Recombinant
Signal Binding Protein for Immunoglobulin Kappa J (RBPJκ), which
triggers displacement of co-repressors with the co-activators
MAML and SKIP, allowing transcription of the Notch target genes,
which include the Hairy Enhancer of Split (Hes) family.41, 42
Mutations of the Notch family are known to be associated with
aberrant liver development. For example, loss of function
mutations of JAG1 and less frequently NOTCH2 result in Alagille’s
syndrome; an autosomal dominant disorder resulting in a failure
of development of the intrahepatic bile ducts leading to
cholestasis and jaundice.43 Transforming mutations of Notch are
not, however, observed in CC.44–46 Rather it appears to be
activation of wild-type signalling that leads to ductular prolifera-
tion and/or a change of lineage commitment in hepatocytes, as
has been exemplified by studies over-expressing wild type N1-ICD
in hepatocytes to produce CC.37 It should, however, be stated that
the precise role of Notch in liver cancer development is complex.
Over-expression of N1-ICD under albumin and αFP promoters in
developing mouse liver results in HCC with 100% penetrance
without the appearance of CC.47 Furthermore, studies using
blocking antibodies against Notch1 results in a reduction in HCC
but an increase in CC, whereas blocking Notch2 or Jag1 reduced
CC burden.48 Studies of other oncogenes including MYC and RAS,
have demonstrated that precise levels of expression are critical to
outcome.49 It is likely that transgenic models using N1-ICD
overexpression result in supra-physiological levels of Notch
activity that are unlikely to occur naturally in response to
endogenous ligand-driven receptor activation. A small number
of studies have, therefore, sought to characterise the role of the
four Notch receptors in human CC. These have shown Notch1, 2
and 3 to be over-expressed human CC compared to nearby
healthy or benign diseased liver and that development of CC can
be inhibited in vitro and in vivo with small molecule inhibitors of
the gamma-secretase complex (GSIs).50, 51 Furthermore, there is
evidence that genetic deletion of the atypical receptor Notch3 can
Fig. 3 Notch is over-activated in CC and drives tumour cell survival. Schematic micrograph of the provision of Notch ligand (Jagged1) by
myofibroblasts in the CC stroma; triggering Notch activity in adjacent CC cells. Notch1 and the atypical Notch3 receptor are over-expressed in
human and rodent models of CC, and both appear to drive CC proliferation. Notch1 acts via the canonical pathway, releasing Notch1
intracellular domain (N1-ICD), which translocates to the nucleus, drives transcription of classical Notch effectors including Hes1, which then
promotes proliferation through expression of genes including Cyclin E. Notch3 appears to stimulate activity through the AKT/PI3K cell survival
pathway independent of the effector of canonical Notch, RBPJκ. A further level at which the pathway can be therapeutically targeted is the
point of receptor cleavage in the membrane. Inhibitors of the enzyme complex gamma-secretase have demonstrated anti-tumoural activity in
cell culture systems, xenografts and toxin driven models in rat
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inhibit CC development and progression in mouse and that
Notch3 is able to promote tumour cell survival through activation
of the PI3K/AKT pathway.52 Notch3 differs structurally from the
more intensively studied Notch1 and Notch2, in that it exhibits a
particularly short transactivation domain; thought to account for
its weaker transcriptional activity, as well as lacking some of the
extracellular EGFR repeats of Notch1 and 2 (refs 53, 54). The
precise route by which it is able to trigger PI3K/AKT signalling
remains unclear, however in vitro data suggest that this is not
dependent on the effector of classical Notch, RBPJκ. These new
data, therefore, offer hope for a novel therapeutic approach,
having the potential therapeutic advantage that specific Notch3
blockade might bypass toxicities associated with Notch1 and
gamma secretase inhibition.55
Other signals of cell identity implicated in liver tumorigenesis
include the mammalian Hippo-Salvador pathway. This pathway is
tonically active in hepatocytes via the kinases Mst1 and Mst2,
acting to control hepatocyte proliferation and act as tumour
suppressors via phosphorylation and, therefore, suppression of the
downstream target Yes-associated protein (Yap). Genetic deletion
of Mst1 and Mst2 results in massive liver overgrowth and
eventually HCC development.56 Disruption of the pathway
through liver-specific knock out of WW45, a homolog of
Drosophila Salvador, similarly results in liver enlargement accom-
panied by an HPC response, mediated through phosphorylation
and hyperactivation of the downstream effector, Yap. Eventually
these animals develop tumours exhibiting mixed HCC/CC
characteristics; thought to derive from the expanded HPC pool.57
Furthermore, transposon-delivery of YAP and constitutively
activated AKT (myr-AKT) results in the development of CC in
mouse when coupled with BDL, with tumours exhibiting biliary
but not hepatocellular markers, confirming YAP to be oncogenic
in CC.58 YAP has been shown to be activated in human disease
and is thought to promote CC growth via interaction with TEAD
transcription factors to stimulate proliferation, inhibit apoptosis
and promote angiogenesis.59
Wnt is a central regulator in many epithelial systems including
the skin, intestine and gut where canonical, β-catenin-dependent
WNT signalling drives stem cell and differentiated cell proliferation
by inducing the transcription of a number of target genes
including MYC and CCND2 (ref. 60). Mutations in the core
canonical Wnt pathway have been shown to drive several
gastrointestinal and other cancers, most notably colorectal cancer
where mutations in APC and less so in beta-catenin are known
oncogenes.61 Recent exome studies have failed to identify these
canonical mutations in CC, with no APC, β-catenin or Axin
mutations found.62 In a subset of liver fluke-associated intrahepa-
tic CCs, however, mutations in the E3 ligase, RNF43 ((Ring Finger
Protein 43, a negative regulator of Wnt signalling) were found in
7.4% of CC from patients with liver fluke and 3.5% of non-liver
fluke-associated CC. RNF43 normally functions to turn over the
Frizzled (Fzd) receptor following ligand binding by ubiquitinating
Fzd and targeting it for degradation. R-spondin and Lgr5
negatively regulate RNF43 (and its homologue ZNRF3) thereby
potentiating Wnt signalling through the canonical pathway. Loss
of function mutations in RNF43 that, therefore, promote Wnt
signalling through failing to downregulate the receptor following
stimulation thus allow the Fzd receptor to be hyperactivated.63
Despite the lack of core mutations, it remains that there is a high
level of canonical Wnt activity in sporadic CC, typified by high
levels of nuclear b-catenin of CC cells in ~ 76% of cases. Recent
work has demonstrated that activation of the Wnt pathway is
achieved through the influx of inflammatory macrophages in the
tumour stroma which are able to secrete Wnt ligands, particularly
WNT7B, which acts upon the epithelial component of the tumour
to drive proliferation and tumour growth.64, 65 Of therapeutic
importance, pharmacological inhibition of Wnt signalling either at
the point of transcription by preventing binding to CtBP or
through inhibition of ligand secretion through inhibition of the
MBOAT-family member Porcupine, reduces both the size fre-
quency of tumours in rat and mouse CC models by disrupting the
balance of proliferation and apoptosis.64 Further evidence of
disruption of the canonical Wnt pathway has been through
demonstration of methylation of Wnt pathway regulators,
particularly the secreted frizzled-related protein family (SFRPs),
which act as soluble negative modulators of Wnt signalling.66
Epigenetic silencing of SFRP2 is proposed to act to stabilise beta-
catenin as competition at the Frizzled receptor is reduced or lost,
although in this study no correlation was demonstrated between
SFRP2 and beta-catenin positivity (nuclear or cytoplasmic) in
human tissue.
As well as proliferation, the canonical Wnt pathway is also
capable of regulating the expression of transcribed-ultraconserved
regions (T-UCRs), long non-coding RNAs, which are involved in
various cancers. Recently, uc.158, a T-UCR downstream of the Wnt/
β-catenin pathway, has been found to be increased in TAA-
induced rat and human CC but not in normal biliary epithelium.
Furthermore, the TAA-induced rats treated with Wnt inhibitors
had reduced levels of uc.158, suggesting the effects of Wnt
signalling in CC might not simply be driving proliferation, but also
feed into a number of secondary pathways through T-UCR
regulation.67
INFLAMMATION, FIBROSIS AND REPAIR: THE TUMOUR
STROMA
In their seminal paper, Hanahan and Weinberg described six
adaptations a cell may acquire in order to escape the homeostatic
processes, which enable it to function as part of an organ.68 These
characteristics; self-sufficiency in growth signals and the ability to
evade growth supressing signals, ability to proliferate indefinitely
and escape death signals, angiogenesis and metastatic potential,
describe a cell that has acquired the ability to function beyond its
role as part of an organ system, and is more like its own organism.
It is becoming clear that as well as these changes, a seventh
hallmark of cancer is its ability to remodel the inflammatory and
wound healing response to organ injury to promote growth and
evade destruction by the adaptive immune system. As previously
discussed, CC commonly arises on a background of cholestatic
injuries, such as PSC and liver fluke infection. These injuries,
although diverse in origin, share a phenotype of cholangiocyte
damage, a pro-inflammatory immune environment, deposition of
extracellular matrix proteins and consequent peri-ductular scar
formation. A defining feature of CC is its prominent desmoplastic
stroma consisting of α-smooth muscle actin (α-SMA)-positive
cancer-associated fibroblasts and numerous immune cell types
including tumour-associated macrophages (TAMs), neutrophils
and vascular endothelial cells.69 The presence of a well-developed
fibrous stroma negatively correlates with CC survival and more
recent studies have established the importance of the tumour
stroma in maintaining tumorigenic identity of CC, presenting the
possibility of therapeutically targeting the stroma.70 In this section,
we will discuss the cellular crosstalk between these stromal cells
and CC cells, and the implications of these interactions with
respect to the pathogenesis of CC and potential therapeutic
targeting of these pathways.
CAFs are activated α-SMA+ mesenchymal cells that can be
derived from activated hepatic stellate cells, the pericyte of the
liver and potentially from other cells sources.71–73 The prevalence
of α-SMA+ CAFs in tumours correlates with poor clinical outcomes
in CC patients.72, 74 Investigation of interactions between CAFs
and tumour cells show that CAFs support many of the malignant
features of CC including proliferation, migration and evasion of
apoptosis via secreted factors.73 An example of this is paracrine
Hedgehog (HH) signalling. Hedgehog is an established regulator
of cell fate in the mammalian liver and in regeneration the
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obligate intermediate of Hedgehog signalling, Smoothened (SMO)
acts to control accumulation of activated myofibroblasts and
progenitor cells following injury, integrating other pathways
including Wnt and TGFβ for co-ordination of the fibrotic and
regenerative responses.75 Furthermore, Hedgehog appears to also
regulate Yap1 in stellate cells, activating genes to trigger the
transition to activated myofibroblasts and promote fibrosis.76
Human CC cells appear to both express and be responsive to the
Hedgehog ligand Sonic Hedgehog (Shh), and Shh pathway
inhibition reduces CC growth, invasion and migration and
promotes CC cell apoptosis.77 Secretion of PDGF-BB signalling
by CAFs further reinforces CC survival by augmenting Hh
signalling in CC cells via upregulation of SMO resulting in
resistance to TRAIL-mediated apoptosis.78
With regard to in vitro CAF data, co-culture of CC cells with
mesenchymal cells induces secretion of several cytokines/chemo-
kines including EGF, IGF-1, PDFG-BB and TGF-β1 in CC cells. The
co-culture experiments suggest a two-way trophic effect as this
induces EGF and TGF-β1 secretion by LX-2 stellate-like cells.79 HB-
EGF produced by CAFs or CC cells themselves induces proliferation
and EMT of CC cells and is reinforced by CC-derived TGF-β1.80, 81
PDGF-D secreted by neoplastic biliary epithelial cells also increases
motility of fibroblasts, which may be important for the develop-
ment of the tumour stroma.82 Although CAF-CC interactions
promote CC survival, activation of hepatic stellate cells into
activated myofibroblasts is accompanied by the upregulation of
the pro-apoptotic protein, Bak. This property has been used to
specifically induce apoptosis in CAFs in an orthotopic rat model of
CC, using the Bcl-inhibitor drug navitoclax, which limited tumour
stroma formation, reduced tumour burden and significantly
improved animal survival providing promising evidence that
therapies targeting CAF viability may limit CC growth.83
In addition to EGF/EGFR interactions, the malignant properties
of CC cells are enhanced by the SDF/CXCR4 pathway and IL-1β
-CXCL5, which also interface with the infiltrating immune
compartment of the tumour stroma. Stromal SDF-1 signals to
CXCR4+ CC cells to increase their migratory potential and
resistance to apoptosis via p-AKT and p-ERK signals.84, 85 This
interaction is enhanced by mononuclear cell-derived TNF, which
modulates CXCR4-dependent migration.85 Autocrine CXCL5 from
CC cells also activates AKT and ERK pathways, increases CC
motility and its secretion is enhanced by CAF-secreted IL-1β.86
CXCL5 is a potent neutrophil chemoattractant in CC and its
expression is positively correlated with the numbers of α-SMA+
CAFs and CD66b+ neutrophil infiltration.86 Although the role of
tumour-associated neutrophils (TANs) has not been extensively
studied, neutrophils recruited to the CC niche increase tumour
growth and metastatic potential, and correlate with reduced post-
operative survival and increased post-operative recurrence of
disease, suggesting that targeting the trafficking of TANs to the
tumour niche might provide a viable therapeutic intervention
following tumour resection in CC.86, 87
The major compartment of infiltrating immune cells in CC are
TAMs, which correlate with poor survival, increased tumour
recurrence and metastasis.88, 89 TAMs are most likely recruited
from a subset of circulating CD14+/CD16+ monocytes, which is
elevated in CC patients,89 to the tumour microenvironment where
they give rise to TAMs, which are actively patterned towards an
‘M2’-like CD163+ phenotype88, 90 and express proteins that
promote tumour growth and progression including matrix
metalloproteases,88, 89 Wnt ligands (discussed above)64, 65and
cytokines such as TNF, IL-4, IL-6, IL-10 and TGFβ, which promote
tumour progression by inducing EMT.88, 91, 92 The effect of
deleting TAMs has been shown by Boulter et al.64 in the rat TAA
model of CC, here the deletion of TAMs by liposomal chlodronate
significantly reduced tumour size, induced tumour cell apoptosis
and reduced Wnt signalling.
HOW NOVEL DATA WILL HELP OVERCOME CHALLENGES IN
THE FIELD OF CC
There are several clinical factors that lead to the poor prognosis of
CC: (1) A significant factor is the delay in diagnosis and patients
often present at a point where curative surgery is not possible.
Clearly, the identification of secreted biomarkers (either made by
the tumour, the stroma or the immune system in response to the
CC) would have great utility in the potential early diagnosis of CC.
This would be particularly useful where there is already an
inflammatory process affecting the bile ducts such as PSC or fluke
infection that can pre-dispose to CC. (2) the lack of effective
therapy to unresectable CC. Here recent work detailing the
heterogeneity of CC and the signals and cell processes that drive
CC could be particularly useful. Molecular analysis of the tumour
can potentially lead to treatment stratification based upon the
main cancer drivers upregulated in that particular tumour.
Likewise, the recognition that there is heterogeneity in the
potential cell of origin helps us to unpick future targets with
potentially greater specificity. This is a timely approach with the
growing recognition and emphasis placed upon personalised
medicine. In practical terms this could be from cancer brushings
and biopsies either analysed directly for their molecular profiles or
as research protocols being grown as organoids to test sensitivity
to chemotherapies and other agents.
SUMMARY
Recent rapid process has been made in understanding the signals
driving CC. These have often been the same signals that have
been described in bile duct development and regeneration
following injury such as Wnt and Notch. The clarification of the
potential for hepatocytes and cholangiocytes to act as the cell of
origin for CC has opened the pathway to understand further the
drivers for CC. There has been an increasing recognition that the
tumour stroma is an important component of the CC, providing
trophic signals to the epithelial cancer and potentially providing
resistance to chemotherapy. Understanding the signals and
mechanisms that drive CC will help the development of novel
therapies and importantly the development of personalised
therapy for CC. The next few years are likely to see continued
progress into the diagnosis and treatment of CC, information that
is greatly needed for this devastating cancer.
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